

R. Jonathan Lara, DO, FAOCO

April 26, 2015 24th Annual Southwestern Conference on Medicine

• **Men** are more likely to experience hearing loss than women.

- Approximately 17 percent (36 million) of American adults report some form hearing loss.
- About 2 to 3 out of every 1,000 children in the United States are born deaf or hard-of-hearing.
 - Nine out of every 10 children who are born deaf are born to parents who can hear.



- The NIDCD estimates that ~15 percent (26 million) of Americans between the ages of 20 and 69 have high frequency hearing loss due to exposure to loud sounds or noise at work or in leisure activities.
- Only 1 out of 5 people who could benefit from a hearing aid actually wears one.
- Three out of 4 children experience ear infection (otitis media) by the time they are 3 years old.




- Strong relationship between age and reported hearing loss:
 - 18 percent of American adults 45-64 years old, 30 percent of adults 65-74 years old, and 47 percent of adults 75 years old or older have a hearing impairment.
- Roughly 25 million Americans have experienced tinnitus.
- Approximately 4,000 new cases of sudden deafness occur each year in the United States.




- Approximately 615,000 individuals have been diagnosed with Ménière's disease in the United States. Another 45,500 are newly diagnosed each year.
- One out of every 100,000 individuals per year develops an acoustic neuroma (vestibular schwannoma).



HEARING ANATOMY & FUNCTION










AUDIOGRAM




TYPES OF HEARING LOSS

- **1. Sensorineural** Hearing Loss (nerve loss)
- 2. **Conductive** Hearing Loss
- 3. **Mixed** Hearing Loss (both nerve and conductive loss)



CONDUCTIVE HEARING LOSS



SENSORINEURAL HEARING LOSS ETIOLOGIES

- 1. Infectious:
 - Meningitis, Herpes virus, HIV, Mumps, Rubella, Rubeola, Mycoplasma, Toxoplasmosis, Syphilis, Lyme disease
- 2. Autoimmune

Lupus erythematosus, Cogan's syndrome, Wegener's granulomatosis

3. Traumatic

Perilymph fistula, T-bone fracture, Acute blast injury



SNHL ETIOLOGIES

4. Vascular

 Vertebrobasilar insufficiency (VBI), Sickle cell disease, Hyperviscosity syndromes, Waldenstrom's macroglobulinemia, Polycythemia vera, thrombocythemia

5. Neurologic

Multiple sclerosis, Migraine

6. Neoplastic

Acoustic neuroma, Meningioma, Metastasis, Leukemia, Myeloma



SNHL ETIOLOGIES

7. Iatrogenic

Ototoxic Meds, Otologic surgery

8. Congenital

Hereditary, Toxic, Infectious, Spontaneous

9. Toxic

Chronic noise

10. Idiopathic Sudden SNHL



SNHL: HISTORY

- Onset (sudden vs. progressive)
- Duration
- Fluctuations in hearing
- Associated symptoms:
 - tinnitus, **vertigo**, imbalance, aural fullness
- h/o otologic surgery or recurrent AOM, head trauma, vascular disease, autoimmune disease
- Family history of hearing loss




SNHL: PHYSICAL EXAM

- Full head and neck exam
- Otoscopic exam
 - Pneumatic otoscopy / Tympanometry
- Tuning forks (Weber & Rinne)
- Cranial nerve exam
- Cerebellar exam/Balance testing as appropriate



SNHL: PHYSICAL EXAM



<u>WEBER TEST</u>: typically with a 512 Hz tuning fork

- <u>Normal</u> = sound heard centrally or in both ears
- <u>unilateral SNHL</u> should lateralize to *better* hearing ear,
- <u>unilateral CHL</u> should lateralize to *diseased* ear




SNHL: PHYSICAL EXAM

<u>Rinne Test</u>: compare air conduction (AC) and bone conduction (BC); place tuning fork ≤ 1 cm of the EAC (AC)and then place on the mastoid (BC);

- <u>Positive</u> = SNHL (GOOD)
 - tuning fork heard better by AC
 - = normal or most SNHL
- Negative CHL

 BC is perceived louder than AC
 CHL >15–30 dB HL or severe to profound SNHL with cross-over





WEBER & RINNE TEST REVIEW

Table 4. Recommended Technique for Weber and Rinne Testing

Weber Test	Rinne Test	
 Place vibrating tuning fork (256 or 512 Hz) at midline of forehead or on maxillary teeth (not false teeth) 	 Place vibrating tuning fork (256 or 512 Hz) over the mastoid bone of one ear, then move the tuning fork to the entrance of the 	
2. Ask where the sound is heard; it is normal to hear at	ear canal (not touching the ear)	
the midline or "everywhere"	2. The sound should be heard better via air conduction (at the	
3. If the sound lateralizes to one ear then:	entrance to the ear canal).	
a. There is a CHL in that ear, OR	3. If the sound is heard better by bone conduction, then there is a	
b. There is SNHL in the opposite ear	CHL in that ear.	
	Repeat for the other ear.	

Abbreviations: CHL, conductive hearing loss; SNHL, sensorineural hearing loss.



SNHL: WORKUP

- Full audiogram with pure tones, speech recognition, and word recognition
- For sudden sensorineural hearing loss or asymmetric sensorineural hearing loss: MRI + gadolinium



PRESBYACUSIS

- Age-related hearing loss
- 40% U.S. population >75 y/o affected
- Often familial (<u>>50%</u>)
- Bilateral and symmetric



PRESBYACUSIS: TREATMENT

Treatment

- Hearing aids
- Assistive listening devices
- Cochlear Implantation



NOISE INDUCED HEARING LOSS (NIHL)

- Most common cause of preventable SNHL
- Most frequently occurs from exposure through years (> 90dB)
- Can result from single exposure to very loud noise (>120-130 dB)
- Typically bilateral and symmetric



NIHL: BACKGROUND

3 types noise:


- Continuous
- Impulse (eg., gun)
- Impact

2 types exposure:


- Chronic
- Acute

2 types damage:

- TTS (temporary)
- PTS (permanent)



CHRONIC NIHL: AUDIOGRAM



Years Exposure



OTOTOXIC MEDICATIONS

Macrolides

High frequency SNHL, tinnitus, vertigo

Usually reversible within 2 weeks

Unknown mechanism

Vancomycin

High freq SNHL progresses to bilateral profound SNHL

-ASA

Doses > 2700 mg/day

Affects stria vascularis, reversible



OTOTOXIC MEDICATIONS

Antineoplastics/cisplatinum

- Begins with high freq HL, progresses as total dose accumulates
- Irreversible when profound deafness occurs
- Can be vestibulotoxic
- Affects OHC
- Loop diuretics/ethacrynic acid
 Affects stria vascularis, rarely permanent
- Phosphodiesterase type 5 inhibitors (Viagra > Levitra, Cialis)
 Unknown mechanism; question of nitric oxide effects on ear



PERILYMPHATIC FISTULA (PLF)

- <u>Definition</u>: Communication between perilymph space and middle ear/mastoid
- Etiology
 - Increased pressure/trauma→communication→Decreased perilymph volume→2^{ndary} endolymphatic hydrops→symptoms
- Potential causes (rare):
 - Otologic surgery (stapedectomy)
 - Head trauma
 - SCUBA diving
 - Congenital ear malformation
 - Forced valsalva / suppressed sneezing



NEOPLASIA

Acoustic tumors:

- Most common: Acoustic Neuroma (misnomer) = Vestibular Schwanomma
- Usually present with gradually progressive SNHL
- 1% of patients with asymmetric SNHL have acoustic tumors



AAO-HNS GUIDELINES – 2012

Guideline

Clinical Practice Guideline: Sudden Hearing Loss

Robert J. Stachler, MD¹, Sujana S. Chandrasekhar, MD², Sanford M. Archer, MD³, Richard M. Rosenfeld, MD, MPH⁴, Seth R. Schwartz, MD, MPH⁵, David M. Barrs, MD⁶, Steven R. Brown, MD⁷, Terry D. Fife, MD, FAAN⁸, Peg Ford⁹, Theodore G. Ganiats, MD¹⁰, Deena B. Hollingsworth, RN, MSN, FNP¹¹, Christopher A. Lewandowski, MD¹², Joseph J. Montano, EdD¹³, James E. Saunders, MD¹⁴, Debara L. Tucci, MD, MS¹⁵, Michael Valente, PhD¹⁶, Barbara E. Warren, PsyD, MEd¹⁷, Kathleen L. Yaremchuk, MD, MSA¹⁸, and Peter J. Robertson, MPA¹⁹

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Abstract

Objective. Sudden hearing loss (SHL) is a frightening symptom that often prompts an urgent or emergent visit to a physician. This guideline provides evidence-based recommendations for the diagnosis. management. and follow-up of patients who pres-



Otolaryngology-Head and Neck Surgery 146(15) SI-S35 © American Academy of Otolaryngology-Head and Neck Surgery Foundation 2012 Reprints and permission: sagepub.com/journalsPermissions.nav DOI: 10.1177/0194599812436449 http://otojournal.org

of medical interventions, and the limitations of existing evidence regarding efficacy; and (3) counsel patients with incomplete recovery of hearing about the possible benefits of amplification and hearing-assistive technology and other supportive measures. The panel made *recommendations* that clinicians should (1) assess patients with presumptive SSNHL for bilateral SHL, recurrent episodes of SHL, or focal neurologic findings; (2) diagnose presumptive ISSNHL if audiometry confirms a 30-dB hearing loss at 3 consecutive frequencies and an underlying condition cannot



CLINICAL PRACTICE GUIDELINE SUMMARY

Table 3. Summary of Evidence-Based Statements

Management of Patients with Sudden Hearing Loss (Evidence-Based Statement)

Statement Strength

Diagnosis	
Exclusion of conductive hearing loss (Statement 1)	Strong recommendation
Modifying factors (Statement 2)	Recommendation
Computed tomography (Statement 3)	Strong recommendation against
Audiometric confirmation of idiopathic sudden sensorineural hearing loss (Statement 4)	Recommendation
Laboratory testing (Statement 5)	Strong recommendation against
Retrocochlear pathology (Statement 6)	Recommendation
Shared decision making	
Patient education (Statement 7)	Strong recommendation
Treatment	
Initial corticosteroids (Statement 8)	Option
Hyperbaric oxygen therapy (Statement 9)	Option
Other pharmacologic therapy (Statement 10)	Recommendation against
Salvage therapy (Statement 11)	Recommendation
Follow-up	
Outcomes assessment (Statement 12)	Recommendation
Rehabilitation (Statement 13)	Strong recommendation

Robert J. Stachler et al. Otolaryngology -- Head and Neck Surgery 2012;146:S1-S35

Copyright © by American Academy of Otolaryngology- Head and Neck Surgery





IDIOPATHIC SUDDEN SENSORINEURAL HEARING LOSS (ISSNHL)

- Theories:
 - Viral
 - Autoimmune (autoimmune inner ear disease AIED)
 - Vascular
 - Intracochlear membrane breaks



ISSNHL: VIRAL

- Current belief viral cochleitis causes the majority of cases of ISSNHL
- 1983 Wilson and colleagues
 - Viral seroconversion rates greater in patients with ISSNHL (63%) compared to control (40%)
 - Influenza B
 - Mumps
 - Rubeola
 - VZV



ISSNHL: VIRAL

- 1981-Veltri *et al*.
 - 65% seroconversion
- 1986 Schuknecht and Donovan
 - Temporal bone studies (n. 12)
 - ISSNHL vs. cases of known viral labyrinthitis
 - Similar pathologic findings
 - Atrophy of the organ of Corti, tectorial membrane, stria vascularis, cochlear nerve, and vestibular organ



ISSNHL: VIRAL




FIG. 2. Light microscopy of the organ of Corti in experimental herpes simplex virus type 1 labyrinthitis. Extensive destruction of the organ of Corti and supporting cells. The tectorial membrane is disrupted from the sensory cells but has a normal appearance (arrow) (bar = 100μ m).

ISSNHL

- New **Sleep apnea** linked to sudden hearing loss
 - No causility proven
 - Sleep apnea causes major inflammation in the bloodstream/brain promoting vascular complications
 - Need for prospective studies, and causality studies with treatment trials (i.e., improved sleep apnea, improved hearing).

Arch Otol Head Neck Surg. 2012; 138 [1]:55.



ISSNHL: TREATMENT

- 90% of cases will be Idiopathic
- Treat known causes by addressing the underlying condition



ISSHNL: TREATMENT

- Therapy for ISSNHL is controversial
- Difficult to study
 - High spontaneous recovery rate
 - Low incidence
 - Makes validation of empiric treatment modalities difficult



ISSNHL: TREATMENT

- Proposed treatment modalities
 - Anti-inflammatory steroids, cytotoxic agents
 - e.g., **Prednisone** lmg/kg/day (80mg) PO QD taper over 2 weeks.
 - Diuretics
 - Antiviral agents



General Guidelines for Corticosteroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)

	Oral Corticosteroids	Intratympanic Corticosteroids
Timing of treatment	Immediate, ideally within first 14 days. Benefit has been reported up to 6 weeks following onset of sudden sensorineural hearing loss (SSNHL)	Immediate Salvage (rescue) after systemic treatment fails
Dose	Prednisone I mg/kg/d (usual maximal dose is 60 mg/d) or Methylprednisolone 48 mg/d or Dexamethasone 10 mg/d	Dexamethasone 24 mg/mL or 16 mg/mL (compounded), or 10 mg/mL (stock)Methylprednisolone 40 mg/mL or 30 mg/mL
Duration/frequency	Full dose for 7 to 14 days, then taper over similar time period	Inject 0.4 to 0.8 mL into middle ear space every 3 to 7 days for a total of 3 to 4 sessions
Technique	Do not divide doses	Anterosuperior myringotomy after topical anesthetic Inject solution into the posterior inferior quadrant via narrow-gauge spinal needle to fill middle ear space Keep head in otologic position (one side down, affected ear up) for 15 to 30 minutes
Monitoring	Audiogram at completion of treatment course and at delayed intervals	 Audiogram before each subsequent injection, at completion of treatment course, and at delayed intervals Inspect tympanic membrane (TM) to ensure healing at completion of treatment course and at a delayed interval
Modifications	Medically treat significant adverse drug reactions, such as insomnia Monitor for hyperglycemia, hypertension in susceptible patients	May insert pressure-equalizing tube if planning multiple injections, but this increases risk of TM perforation May consider adding round window transport facilitator

Table 9. General Guidelines for Corticosteroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)^a

^aThis table is designed to provide guidance for systemic and intratympanic steroid treatment for SSNHL. Treatment is routinely individualized by provider and per patient. The most important principles pertain to early institution of high enough dosages of treatment. Prednisone I mg/kg/d or its equivalent and/or adequate concentration of intratympanic dexamethasone or solumedrol should be administered.


Robert J. Stachler et al. Otolaryngology -- Head and Neck Surgery 2012;146:S1-S35



TREATMENT

BAHA (Cochlear / Oticon)

- Bone Anchored Hearing "Aid"
- Surgically implanted pin in the skull, using a vibrating digital hearing amplfication device.
- CROS/BICROS
 - <u>Contralateral Routing Of Signal</u>





CROS (Contralateral Routing of Signal) candidates typically have one unaidable ear and normal to mild high-frequency hearing loss in the opposite ear.



BiCROS (Bilateral Contralateral Routing of Signal) candidates typically have one unaidable ear and mild to severe hearing loss in the opposite ear.

Mild to severe hearing loss



Selected Conditions That May Be Associated with Bilateral Sudden Hearing Loss.

Cause	Other Features	
Meningitis (infectious, inflammatory, neoplastic)	Headache, fever, abnormal cerebrospinal fluid (CSF) studies, possibly other cranial nerve palsies ²¹¹	
Autoimmune inner ear disease	Fluctuation of hearing may sometimes occur; vertigo may occur in some cases. ⁴¹	
Lyme disease	Erythema chronicum migrans, abnormal CSF, fluctuating bilateral audiovestibular symptoms ²¹²	
Syphilis	Abnormal fluorescent treponemal antibody absorption (FTA-abs) test, bilateral fluctuating hearing loss, tabes dorsalis, multiorgan involvement ²¹³	
Ototoxic medications	Vestibular loss, oscillopsia ^{214,215}	
Trauma	Significant head trauma, barotrauma, temporal bone fractures ²¹⁴	
Herpes zoster oticus (Ramsay-Hunt syndrome)	Otalgia, pinna and/or ear canal vesicles, facial nerve paresis, positive viral titers, positive viral cultures ²¹⁶	
Human immunodeficiency virus (HIV) otitis	Positive HIV titers, altered T cell counts, and often other cranial neuropathies may be associated with mastoiditis out of proportion to clinical complaints. ^{217,218}	
Lead poisoning	Learning disabilities, other stigmata of lead poisoning ²¹⁹	
Genetic disorders	May be syndromic or nonsyndromic ^{220,221}	
MELAS (metabolic encephalopathy, lactic acidosis and stroke-like episodes)	Periods of confusion, elevated serum lactic acid levels around times of attacks, stroke- like spells, magnetic resonance imaging (MRI) white matter signal changes, migraine- like headaches, seizures, diabetes, mitochondrial gene mutation (Mt-RNRI, Mt-TSI, POLG genes) ^{222,223}	
Other mitochondrial disorders	Variable phenotypes ²²⁴	
Bilateral synchronous internal auditory artery occlusion associated with vertebrobasilar vascular disease	Vertigo, dysarthria, facial weakness, ataxia, nystagmus, unilateral numbness, abnormal computed tomography or magnetic resonance angiogram of the vertebrobasilar vasculature ^{48,50,225-227}	
Cogan syndrome	Nonsyphilitic interstitial keratitis of the cornea, hearing loss, vertigo ⁴⁰	
Neoplastic (neurofibromatosis II, bilateral vestibular schwannomas, intravascular lymphomatosis, others)	Abnormal brain MRI or cerebrovascular imaging study ²²⁸⁻²³⁰	
Sarcoidosis	Pulmonary symptoms, bilateral vestibular loss, elevated serum angiotensin-converting enzyme level or abnormal Gallium scan ^{231,232}	
Hyperviscosity syndrome	Mucous membrane bleeding, neurologic and pulmonary symptoms, associated retinopathy ²³³	

 Table 6. Selected Conditions That May Be Associated with Bilateral Sudden Hearing Loss

Robert J. Stachler et al. Otolaryngology -- Head and Neck Surgery 2012;146:S1-S35

Copyright © by American Academy of Otolaryngology- Head and Neck Surgery





AUTOIMMUNE INNER EAR DISEASE (AIED)

- 1979 McCabe
 - Described patients with bilateral rapidly-progressive SNHL (BRPSNHL)
 - Proposed the term autoimmune inner ear disease (AIED)
 - Evidence of autoimmunity
 - Lymphocyte inhibition test
 - Substantial hearing improvement with steroids



AIED

Clinical characteristics

Middle-aged females

BRPSNHL

- Absence of systemic immune disease
- 50% with dizziness
- Light-headedness and ataxia more common than vertigo
- Episodes multiple, daily
- Hearing loss sudden, rapidly progressive, or protracted



AIED: EXAMPLES



"<u>RUSH LIMBAUGH'S</u> severe-to-profound, bilateral, rapidly progressive hearing loss generated considerable public interest in sudden deafness. In his case, its cause was reportedly an autoimmune disease of the cochlea."

- CNN.com



"<u>FOXY BROWN</u>, real name Inga Marchand, has revealed that she is slowly losing her hearing . She first noticed a problem when her label boss, Jay-Z told her the sound levels on her new record were way too high when she had thought they were perfect."



AIED

Diagnosis

- Based on Hearing loss and response to treatment
- Hughes
 - Lymphocyte transformation test
 - Sensitivity 50-80%
 - Specificity 93%
 - Positive predictive value 56-73%
 - Western blot
 - Sensitivity 88%
 - Specificity 80%
 - Positive predictive value 92%



AIED TREATMENT

- 1. **Prednisone** lmg/Kg/day for 4 weeks
- 2. Slow taper
- 3. Relapse during taper restart
- 4. Slow taper
- 5. If relapse during taper **Cytotoxic** agent
 - Methotrexate
 - Cyclophosphamide
 - Monitor electrolytes, LFTs, blood counts




VASCULAR

- <u>Etiologies</u> Embolism, vasospasm, hypercoagulable states/sludging
- <u>Pathophysiology</u> anoxia to vestibulocochlear apparatus
- Cochlea is intolerant to disruption of blood supply
 - 1957 Kimura and Perlman
 - Clamped the labyrinthine artery in guinea pigs
 - Demonstrated irreversible loss of cochlear function after 30 minutes of disruption



VASCULAR ANATOMY



VASCULAR

- Abnormal circulatory states
 - Sickle-cell disease
 - Waldenstrom's macroglobulinemia
 - Hearing loss is usually reversible with tx
 - AICA strokes
 - Cardiopulmonary bypass



PROGNOSIS

- 47%-63% spontaneously resolve
 - Combined patients with all audiogram types
- Prognostic variables:
 - 1. Time since onset
 - 2. Audiogram type (severity of hearing loss)
 - 3. Vertigo
 - 4. Age



CLINICAL PRACTICE GUIDELINE SUMMARY

Table 3. Summary of Evidence-Based Statements

Management of Patients with Sudden Hearing Loss (Evidence-Based Statement)

Diamaria

Statement Strength

Diagnosis	
Exclusion of conductive hearing loss (Statement 1)	Strong recommendation
Modifying factors (Statement 2)	Recommendation
Computed tomography (Statement 3)	Strong recommendation against
Audiometric confirmation of idiopathic sudden sensorineural hearing loss (Statement 4)	Recommendation
Laboratory testing (Statement 5)	Strong recommendation against
Retrocochlear pathology (Statement 6)	Recommendation
Shared decision making	
Patient education (Statement 7)	Strong recommendation
Treatment	
Initial corticosteroids (Statement 8)	Option
Hyperbaric oxygen therapy (Statement 9)	Option
Other pharmacologic therapy (Statement 10)	Recommendation against
Salvage therapy (Statement 11)	Recommendation
Follow-up	
Outcomes assessment (Statement 12)	Recommendation
Rehabilitation (Statement 13)	Strong recommendation

Robert J. Stachler et al. Otolaryngology -- Head and Neck Surgery 2012;146:S1-S35

Copyright © by American Academy of Otolaryngology- Head and Neck Surgery







6340 N. Campbell Ave, #256 Tucson, AZ 85718

- (520) 775-3333
- www.sonoranent.com



R. Jonathan Lara, DO, FAOCO



Thomas S. Kang, MD

